ACELYRIN Inc
NASDAQ:SLRN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.86
8.63
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SLRN stock under the Base Case scenario is 7.19 USD. Compared to the current market price of 4.29 USD, ACELYRIN Inc is Undervalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
ACELYRIN Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for SLRN cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ACELYRIN Inc
Balance Sheet Decomposition
ACELYRIN Inc
Current Assets | 596.6m |
Cash & Short-Term Investments | 562.4m |
Receivables | 30.1m |
Other Current Assets | 4.1m |
Non-Current Assets | 21.7m |
PP&E | 8.7m |
Other Non-Current Assets | 13m |
Current Liabilities | 83.5m |
Accounts Payable | 17.6m |
Accrued Liabilities | 65.2m |
Other Current Liabilities | 754k |
Non-Current Liabilities | 6.6m |
Other Non-Current Liabilities | 6.6m |
Earnings Waterfall
ACELYRIN Inc
Revenue
|
0
USD
|
Operating Expenses
|
-324.8m
USD
|
Operating Income
|
-324.8m
USD
|
Other Expenses
|
60.4m
USD
|
Net Income
|
-264.4m
USD
|
Free Cash Flow Analysis
ACELYRIN Inc
USD | |
Free Cash Flow | USD |
SLRN Profitability Score
Profitability Due Diligence
ACELYRIN Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
ACELYRIN Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
SLRN Solvency Score
Solvency Due Diligence
ACELYRIN Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
ACELYRIN Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SLRN Price Targets Summary
ACELYRIN Inc
According to Wall Street analysts, the average 1-year price target for SLRN is 11.73 USD with a low forecast of 6.06 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for SLRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SLRN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ACELYRIN Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Agoura Hills, California and currently employs 51 full-time employees. The company went IPO on 2023-05-05. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The firm is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. The company is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.
Contact
IPO
Employees
Officers
The intrinsic value of one SLRN stock under the Base Case scenario is 7.19 USD.
Compared to the current market price of 4.29 USD, ACELYRIN Inc is Undervalued by 40%.